Breaking News Updates for the Psychedelics Industry | Page 3 of 9

Psychedelics News

Breaking News

25 Sep 2024

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Enveric Biosciences presented promising preclinical data on their lead drug candidate, EB-003, at the 7th Neuropsychiatric Drug Summit. This non-hallucinogenic, neuroplastogenic DMT analog demonstrated significant reductions in anxiety and depression...

By Madison Roberts

Breaking News

10 Sep 2024

Mindstate Design Labs AI-Designed Trial Gets FDA Approval

Mindstate Design Labs has announced major news, receiving both FDA and European Medicines Agency (EMA) approval to commence human trials of its compound, MSD-001. This approval is a clinical validation...

By Microdose NewsDesk

Breaking News

6 Sep 2024

Psyence Biomed Announces Acquisition of Psilocybin Drug Developer Clairvoyant Therapeutics

Psyence Biomed announces acquisition Clairvoyant Therapeutics and its Phase 2b trial...

By Microdose NewsDesk

Breaking News

13 Aug 2024

FDA Rejected MDMA-Assisted PTSD Therapy: Psychedelic Industry Responds

The FDA's recent rejection of MDMA-assisted therapy for PTSD has sparked significant reactions from the psychedelic and mental health communities. While the decision is seen as a setback, industry leaders...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

14 May 2024

Advancing Mental Health Treatments: The Strategic Collaboration Between Enveric Biosciences and MindBio Therapeutics

In a groundbreaking move within the pharmaceutical industry, Enveric Biosciences (NASDAQ: ENVB) a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety,...

By Madison Roberts

Breaking News, Press Releases

13 May 2024

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

AbbVie and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research...

By Madison Roberts

Breaking News

30 Apr 2024

MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials

MindBio Therapeutics Corp, a clinical stage biopharma company developing innovative psychiatric treatments using microdoses of psychedelic medicines to revolutionize mental health treatments, is delighted to announce the regulatory approval of...

By Madison Roberts

Breaking News

26 Feb 2024

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2A Take-Home Microdosing Trial

MindBio Therapeutics has announced groundbreaking results from a Phase 2a clinical trial involving the take-home microdosing of MB22001 for treating depression. This world-first trial showcased a significant decrease in depression...

By Microdose NewsDesk

Breaking News

12 Dec 2023

Breaking News: MAPS Files New Drug Application With FDA for MDMA-Assisted Therapy

Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result